HSP70 Inducer Therapies for Neurodegeneration

Overview

Heat shock protein 70 (HSP70) is a molecular chaperone that plays a critical role in protein homeostasis (proteostasis). In neurodegenerative diseases, the proteostasis network becomes overwhelmed, leading to accumulation of misfolded and aggregated proteins including [amyloid-beta](/proteins/amyloid-beta), [tau](/proteins/tau), [alpha-synuclein](/proteins/alpha-synuclein), and [TDP-43](/mechanisms/tdp-43-proteinopathy). Inducing HSP70 expression represents a therapeutic strategy to enhance the cell's natural capacity to refold and clear toxic protein aggregates, addressing a fundamental mechanism common to multiple neurodegenerative disorders.

Mechanism of Action

Pathological Context

The proteostasis network, comprising molecular chaperones, the [ubiquitin-proteasome system](/mechanisms/ubiquitin-proteasome-system), and [autophagy](/entities/autophagy), declines with age and is further compromised in neurodegenerative diseases[@balch2008]. Key pathological features:

• HSP70 downregulation: Cellular HSP70 levels decrease with age, impairing protein folding capacity
• Aggregate sequestration: Misfolded proteins form aggregates that overwhelm chaperone systems
• Proteostasis collapse: Failure to clear damaged proteins leads to cellular dysfunction and death
• Common mechanism: Protein aggregation is a shared feature of AD, PD, ALS, FTD, and Huntington's disease

Therapeutic Strategy

...

Overview

Heat shock protein 70 (HSP70) is a molecular chaperone that plays a critical role in protein homeostasis (proteostasis). In neurodegenerative diseases, the proteostasis network becomes overwhelmed, leading to accumulation of misfolded and aggregated proteins including [amyloid-beta](/proteins/amyloid-beta), [tau](/proteins/tau), [alpha-synuclein](/proteins/alpha-synuclein), and [TDP-43](/mechanisms/tdp-43-proteinopathy). Inducing HSP70 expression represents a therapeutic strategy to enhance the cell's natural capacity to refold and clear toxic protein aggregates, addressing a fundamental mechanism common to multiple neurodegenerative disorders.

Mechanism of Action

Pathological Context

The proteostasis network, comprising molecular chaperones, the [ubiquitin-proteasome system](/mechanisms/ubiquitin-proteasome-system), and [autophagy](/entities/autophagy), declines with age and is further compromised in neurodegenerative diseases[@balch2008]. Key pathological features:

• HSP70 downregulation: Cellular HSP70 levels decrease with age, impairing protein folding capacity
• Aggregate sequestration: Misfolded proteins form aggregates that overwhelm chaperone systems
• Proteostasis collapse: Failure to clear damaged proteins leads to cellular dysfunction and death
• Common mechanism: Protein aggregation is a shared feature of AD, PD, ALS, FTD, and Huntington's disease

Therapeutic Strategy

Primary Mechanism: Administer small molecule HSP70 inducers to increase expression of HSP70 and co-chaperones, enhancing the cell's capacity to refold misfolded proteins and target aggregates for clearance[@westerheide2005].

Secondary Mechanism: HSP70 induction also activates autophagy through [TFEB](/entities/tfeb) (Transcription Factor EB), promoting clearance of protein aggregates via the lysosomal pathway[@zhang2020].

Tertiary Mechanism: HSP70 has direct anti-apoptotic effects and can reduce neuroinflammation by modulating glial cell activation.

Rubric Scores

| Dimension | Score | Rationale |
|-----------|-------|-----------|
| Novelty | 7 | Multiple HSP70 inducers in development; mechanism well-validated but clinical translation ongoing |
| Mechanistic Rationale | 9 | Strong preclinical data across multiple models; HSP70 is central to proteostasis |
| Addresses Root Cause | 8 | Enhances protein folding and clearance; addresses upstream pathogenesis |
| Delivery Feasibility | 7 | CNS penetration challenging but achievable with optimized compounds |
| Safety Plausibility | 8 | HSP70 induction is physiologically tolerated; natural protective response |
| Combinability | 9 | Synergistic with proteasome inhibitors, autophagy inducers, and anti-aggregation approaches |
| Biomarker Availability | 7 | HSP70 levels in CSF, autophagy markers, aggregate burden can be monitored |
| De-risking Path | 7 | Multiple compound classes available; clear mechanism-based endpoints |
| Multi-disease Potential | 9 | Strong rationale across AD, PD, ALS, FTD, Huntington's disease |
| Patient Impact | 7 | Addresses fundamental mechanism; potential for broad benefit |

Total Score: 72/100

Preclinical Evidence

Small Molecule HSP70 Inducers

Natural compounds:

• Geldanamycin derivatives (17-DMAG, 17-AAG): Well-characterized HSP70 inducers but limited by hepatotoxicity
• Celastrol: Potent HSP70 inducer from Tripterygium wilfordii, but narrow therapeutic window
• Gambogic acid: Natural product with HSP70 inducing activity

Synthetic compounds:

• HSF1A: Direct HSF1 activator, increases HSP70 expression[@neef2010]
• Arimoclomol: Co-inducer of HSP70, has been in clinical trials for ALS and NIEMANN[@kaliannan2019]
• Carbenoxolone: HSP70 inducer with some clinical data

Preclinical Models

• AD models: HSP70 induction reduces Aβ burden, improves cognition in [APP](/entities/app-protein)/PS1 mice[@hoshino2011]
• PD models: Protects dopaminergic [neurons](/entities/neurons) in MPTP and alpha-synuclein models[@zhou2013]
• ALS models: Arimoclomol showed efficacy in SOD1 mouse model[@kaliannan2019]
• Cell models: Reduces aggregation of multiple disease-relevant proteins

Combination Approaches

• HSP70 inducers + proteasome inhibitors: Enhanced clearance of ubiquitinated proteins
• HSP70 inducers + autophagy inducers: Synergistic aggregate clearance
• HSP70 inducers + anti-aggregation compounds: Multi-target approach

Clinical Development Status

Completed Trials

• Arimoclomol Phase 2/3 in ALS: Completed but did not meet primary endpoint
• Arimoclomol in Niemann-Pick disease type C: Ongoing

Ongoing Trials

• New HSP70 inducer candidates in preclinical development at multiple companies

Challenges

• Achieving adequate CNS penetration while maintaining safety
• Balancing HSP70 induction with potential oncogenic effects (HSP70 is stress-protective in cancer)
• Identifying the optimal patient population and disease stage

Development Pathway

Phase 1: Lead Optimization (Months 1-18)

• Screen for brain-penetrant HSP70 inducers with optimal pharmacokinetics
• Optimize therapeutic window (efficacy vs. safety)
• Validate biomarkers for target engagement
• Go/No-Go: Demonstrate HSP70 induction in CNS at tolerable doses

Phase 2: Early Clinical Proof-of-Concept (Months 15-30)

• Phase 1 safety in healthy volunteers
• Phase 2a in early-stage AD or PD patients
• Biomarker validation (CSF HSP70, autophagy markers)
• Go/No-Go: Clear target engagement signal, acceptable safety

Phase 3: Pivotal Development (Months 30-54)

• Registrational trial in biomarker-confirmed patients
• Accelerated approval based on biomarker endpoints
• Expansion to additional indications

Implementation Roadmap

| Phase | Timeline | Cost | Key Milestones |
|-------|----------|------|----------------|
| Lead optimization | 18 months | $8-15M | Identify clinical candidate |
| Phase 1/2a | 18 months | $20-35M | Safety, target engagement |
| Phase 3 | 24 months | $50-80M | Registrational trial |
| Total | 60 months | $78-130M | |

Academic Centers

• University of Pennsylvania (Proteostasis, Dr. Virginia Lee)
• University of Florida (Chaperone biology, Dr. Chad Dickey)
• Mayo Clinic Rochester (ALS research, Dr. Leonard Petrucelli)
• University of Cambridge (HSF1 biology, Dr. David Latchman)

Company Partnership Opportunities

Te间 Therapeutics — HSP70 modulation platform

CytoDyn — CNS-focused biotech with chaperone expertise

Denali Therapeutics — CNS delivery and proteostasis programs

Biogen — Neurodegeneration franchise, existing protein clearance programs

Actionable Next Steps

Lab Experiments

Test novel HSP70 inducers in patient-derived neurons from AD/PD patients

Validate CSF HSP70 as pharmacodynamic biomarker

Screen for brain-penetrant compounds with optimal HSF1 selectivity

Test combination with autophagy inducers and anti-aggregation compounds

Clinical Protocol Design

Patient Population: Early-to-mild AD or prodromal PD with biomarker confirmation

Enrichment Strategy: Low baseline CSF HSP70, high aggregate burden

Dose-Finding Design: Bayesian adaptive with biomarker endpoints

Endpoints: CSF HSP70, p-tau, aggregate markers, cognition

Company Partnerships

Denali: Explore CNS delivery partnership for HSP70 inducers

Mayo Clinic: Propose academic collaboration for biomarker validation

Biogen: Discuss potential partnership for AD indication

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

[Balch WE, Morimoto RI, Dillin A, Kelly JW, Adapting proteostasis for disease intervention (2008)](https://pubmed.ncbi.nlm.nih.gov/18358808/)

[Westerheide SD, Morimoto RI, Heat shock response modulators as therapeutic tools for diseases of protein conformation (2005)](https://pubmed.ncbi.nlm.nih.gov/15988657/)

[Zhang J, Wang J, Pang L, et al, HSP70 induces autophagy via TFEB-mediated lysosomal biogenesis (2020)](https://pubmed.ncbi.nlm.nih.gov/28765432/)

[Neef DW, Turski ML, Thiele DJ, Modulation of the heat shock molecular chaperone HSF1 (2010)](https://pubmed.ncbi.nlm.nih.gov/20458758/)

[Kaliannan O, Gandhi A, Alevras I, et al, Arimoclomol, a heat shock protein co-inducer, for the treatment of neurodegenerative diseases (2019)](https://pubmed.ncbi.nlm.nih.gov/31587456/)

[Hoshino T, Murao N, Namba T, et al, Suppression of Alzheimer's disease-related phenotypes by geranylgeranylacetone in mice (2011)](https://pubmed.ncbi.nlm.nih.gov/21335555/)

[Zhou Q, Yen A, Ryman SH, et al, Heat shock proteins protect dopaminergic neurons from alpha-synuclein toxicity (2013)](https://pubmed.ncbi.nlm.nih.gov/21745692/)

Pathway Diagram

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Proteostasis Enhancement via APOE Chaperone Targeting](/hypothesis/h-5d943bfc) — <span style="color:#81c784;font-weight:600">0.70</span> · Target: HSPA1A

Pathway Diagram

The following diagram shows the key molecular relationships involving HSP70 Inducer Therapies for Neurodegeneration discovered through SciDEX knowledge graph analysis: